secwatch.observer — SEC 8-K summary
======================================

Issuer:     CEL SCI CORP (CVM)
CIK:        0000725363
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001654954-24-007928
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEL-SCI presents Multikine data: 5yr survival 73% vs 45% control; risk of death halved
--------------------------------------------------------------------------------

- Multikine cut risk of death by 50% in low PD-L1 head and neck cancer patients: 73% survival vs 45% control at 5 years.
- Hazard ratio 0.35 (95% CI 0.19-0.66, log rank p=0.0015).
- Multikine targets low PD-L1 tumor expression, contrasting with checkpoint inhibitors like Keytruda.
- Company working to commence FDA confirmatory Registration Study for Multikine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/0001654954-24-007928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/725363/000165495424007928/cvm_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-007928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer